Literature DB >> 7690925

c-Yes tyrosine kinase activity in human colon carcinoma.

J Park1, A I Meisler, C A Cartwright.   

Abstract

To examine the role of Src-related proteins in human colon carcinoma we measured the tyrosine kinase activity of pp60c-src (Src), p62c-yes (Yes), p56lck (Lck), p59fyn (Fyn), p59hck (Hck), p56lyn (Lyn) and p55c-fgr (Fgr) from colonic cells. Yes activity, similar to that of Src, was 10-20 fold higher in three of five colon carcinoma cell lines and fivefold higher in 10 of 21 primary colon cancers than that in normal colonic cells. Lck activity was present in COLO 205 cells, otherwise Lck, Fyn, Hck, Lyn and Fgr activities were not detected in any of the carcinoma cell lines or cancers tested. Increased Yes activity, like that of Src, was due mostly to increased protein levels and not to an apparent decrease in phosphorylation of Tyr 537, the major mechanisms known to deregulate enzymatic activity. Only those colon carcinoma cell lines with elevated Src and/or Yes tyrosine kinase activity as measured in vitro had elevated levels of three tyrosine-phosphorylated proteins as measured in vivo. Thus, colon carcinoma cells contain active tyrosine kinases and/or inactive tyrosine phosphatases not present in normal colonic cells, and Src and Yes appear to be active kinases in the carcinoma cells. These data, together with those demonstrating decreased Src activity in fully differentiated enterocytes, suggest that down regulation of Src-related tyrosine kinases is important for differentiation, and/or deregulation of the kinases is important for growth and transformation of intestinal epithelial cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7690925

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  33 in total

1.  DHHC20: a human palmitoyl acyltransferase that causes cellular transformation.

Authors:  Jeremiah M Draper; Charles D Smith
Journal:  Mol Membr Biol       Date:  2010-04       Impact factor: 2.857

2.  Activation of c-Yes in hepatocellular carcinoma: a preliminary study.

Authors:  Han Feng; Tsutomu Masaki; Takako Nonomura; Asahiro Morishita; Gong Jian; Seiji Nakai; Akihiro Deguchi; Naohito Uchida; Takashi Himoto; Hisakazu Iwama; Hisashi Usuki; Hisao Wakabayashi; Kunihiko Izuishi; Hitoshi Yoshiji; Kazutaka Kurokohchi; Shigeki Kuriyama
Journal:  World J Gastroenterol       Date:  2006-09-21       Impact factor: 5.742

3.  RACK1, a receptor for activated C kinase and a homolog of the beta subunit of G proteins, inhibits activity of src tyrosine kinases and growth of NIH 3T3 cells.

Authors:  B Y Chang; K B Conroy; E M Machleder; C A Cartwright
Journal:  Mol Cell Biol       Date:  1998-06       Impact factor: 4.272

4.  Plakophilin-2 induced EGFR phosphorylation: a focus on the intracellular activators of EGFR.

Authors:  Kei-Ichiro Arimoto; Stephanie Weng; Dong-Er Zhang
Journal:  Receptors Clin Investig       Date:  2014

Review 5.  Kinase inhibitors in cancer therapy: a look ahead.

Authors:  H H Sedlacek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

6.  Srcasm corrects Fyn-induced epidermal hyperplasia by kinase down-regulation.

Authors:  Weijie Li; Christine Marshall; Lijuan Mei; Joel Gelfand; John T Seykora
Journal:  J Biol Chem       Date:  2006-10-16       Impact factor: 5.157

7.  Adhesion signaling by a novel mitotic substrate of src kinases.

Authors:  Ami S Bhatt; Hediye Erdjument-Bromage; Paul Tempst; Charles S Craik; Mark M Moasser
Journal:  Oncogene       Date:  2005-08-11       Impact factor: 9.867

8.  Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer.

Authors:  John J Arcaroli; Basel M Touban; Aik Choon Tan; Marileila Varella-Garcia; Rebecca W Powell; S Gail Eckhardt; Paul Elvin; Dexiang Gao; Wells A Messersmith
Journal:  Clin Cancer Res       Date:  2010-08-03       Impact factor: 12.531

9.  Tom1l2 hypomorphic mice exhibit increased incidence of infections and tumors and abnormal immunologic response.

Authors:  Santhosh Girirajan; Paula M Hauck; Stephen Williams; Christopher N Vlangos; Barbara B Szomju; Sara Solaymani-Kohal; Philip D Mosier; Kimber L White; Kathleen McCoy; Sarah H Elsea
Journal:  Mamm Genome       Date:  2008-03-15       Impact factor: 2.957

10.  Increases in c-Yes expression level and activity promote motility but not proliferation of human colorectal carcinoma cells.

Authors:  Jane Barraclough; Cassandra Hodgkinson; Alison Hogg; Caroline Dive; Arkadiusz Welman
Journal:  Neoplasia       Date:  2007-09       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.